At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 20 enrolled
Drug / intervention
The isotope 68Ga, NETSPOT and 18F-FDG-PET/CTdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Comparison of NETSPOT Imaging Versus F-FDG-PET in Head and Neck Cancer Patients
In Brief
A Phase 2 clinical trial evaluating The isotope 68Ga, NETSPOT and 18F-FDG-PET/CT for Head and Neck Squamous Cell Carcinoma. Completed, enrolled 20 participants across 1 site.
Detailed Summary
This is a proof-of-concept trial to compare 18F-FDG-PET/CT with NETSPOT (68Ga-DOTA-TATE), a commercially available radiotracer packet that utilizes 68Ga to image SSTR-specific tissue.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHead and Neck Squamous Cell Carcinoma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedJul 2018
Enrollment StartFeb 2019
Primary CompletionApr 2021
TodayJul 2026
First PostedJul 27, 2018
Enrollment StartFeb 1, 2019
Primary CompletionApr 1, 2021
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 7.9 years ago
Interventions
The isotope 68Ga, NETSPOT and 18F-FDG-PET/CTdrug
All patients will undergo 18F-FDG-PET/CT per established protocol. Following 18F-FDG-PET/CT, the patient will undergo NETSPOT imaging